Aims and scope

Expert Opinion on Emerging Drugs [ISSN 1472-8214]; [e-ISSN 1744-7623] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Emerging Drugs addresses the needs of pharmaceutical and academic scientists, research planners, pharmaceutical product managers, clinical opinion leaders and healthcare planners.

Articles include the following key areas:

• Concise background to the subject matter
• Assessment of medical need for alternative or novel therapies
• Assessment of the market and anticipated changes over time
• Summary of current research goals
• Outline of the scientific rationale for the approach(es) considered
• Analysis of the competitive environment
• Discussion of potential development issues
• The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseases

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Emerging Drugs, part of the Expert Collection brand. 

Authors can choose to publish gold open access in this journal and may choose to publish using our Accelerated Publication services.

Read the Instructions for Authors for information on how to submit your article. For any pre-submission enquiries, please contact the Commissioning Editor.